FDA approves Afrezza for pediatric diabetes patients

29. toukokuuta 2026

Raportoinut AI

The U.S. FDA has approved Afrezza for children and adolescents with diabetes ages 6 and older. MannKind Corporation held a conference call on May 29, 2026, to discuss the decision.

MannKind Corporation announced the approval during a call led by CEO Michael Castagna. He described the day as a historic moment for the company, the diabetes community, and young patients. Castagna noted that founder Al Mann had long envisioned the treatment reaching children, and the company is fulfilling that goal.

Liittyvät artikkelit

Illustration showing long COVID patients revitalized by fluvoxamine treatment in a clinical trial, with scientists and physician highlighting study results.

Fluvoksamiini lievittää vaikeaa väsymystä pitkäaikaisesta koronasta kärsivillä

31. maaliskuuta 2026 Raportoinut AI AI:n luoma kuva

Tutkimus osoittaa, että masennuslääke fluvoksamiini vähentää pitkäaikaisesta koronasta kärsivien potilaiden vaikeaa väsymystä. 399 aikuisella tehdyssä satunnaistetussa kokeessa lääkettä verrattiin metformiiniin ja lumelääkkeeseen. Ylilääkäri Judith Bruchfeld pitää tuloksia mielenkiintoisina.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

01. huhtikuuta 2026 Raportoinut AI

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Teknologia

14. kesäkuuta 2026 20.53

FDA approves Afrezza for pediatric diabetes patients

Liittyvät artikkelit

Fluvoksamiini lievittää vaikeaa väsymystä pitkäaikaisesta koronasta kärsivillä

Oral GLP-1 pill shows strong results in diabetes trial

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Dexcom outlines growth plans at 2026 investor day

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

France reimburses Mounjaro and Wegovy for severe obesity

Novo Nordisk heads to South African court over semaglutide copies

Kolme miljoonaa kruunua syöttösolujen astmatutkimukseen

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Semaglutide shows strong weight loss results for adults over 65

Swedish team restores blood sugar control in diabetic mice

Innovative Cape Town clinic boosts outcomes for young kidney patients

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

FDA approves Travere Therapeutics' FILSPARI for FSGS

Tutkimus suosittelee hoitoa kaikille lapsille, joilla on lihavuutta

Tämä verkkosivusto käyttää evästeitä